Emgality (galcanezumab) prior authorization form for migraine/cluster headache prophylaxis
Customize your policy alerts
Sign up for all Highmark Blueshield Neny policy alerts
Know when Highmark Blueshield Neny releases new policies or updates existing guidance.
Monitor payer policy activity
A medication prior authorization form used by Highmark BlueShield for Emgality (galcanezumab) to document clinical indications, prior therapeutic failures/intolerance, dosing (including loading dose), concurrent CGRP use, and reauthorization effectiveness criteria for episodic migraine, chronic migraine, and episodic cluster headache.
No material clinical/coverage changes
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.